Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-120 in late stage exudative AMD
NCT02022501Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jan 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DE-120 in exudative age-related macular degeneration, sponsored by Santen Pharmaceutical. Started Jan 2014; status: completed.
02
Drugs
DE-120
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT02022501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02022501.